The Food and Drug Administration made a mistake Friday by approving a new drug called Vyleesi for women with low sexual desire. This is what happens when drug regulators lower — nearly to the floor — their own risk-benefit standards just so they can pander to special interests.

More on why FDA should have rejected Vyleesi in a moment. First, let’s deal with the Wall Street repercussions of this bad decision, starting with the inevitable, unsurprising but also undeserved jump in the stock price of Palatin Technologies (PTN).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • No position in PTN or AMAG

    I like Adam but sometimes it seems like he lacks impartiality. To nitpick about PTN being up $0.67 vs the “deserved” $0.23 makes one wonder if he has a personal interest in the outcome. Vyleesi is probably a drug the world didn’t need but Adam’s stock analysis is maybe an opinion we didn’t need either. This reads like a Seeking Alpha article not a STAT News piece.

  • Adam has no experience running a company and no IQ on how companies are built. He was dead wrong when he said vyleesi will not be approved and he is pissed with himself and thus this article.

  • I hope Palatin take you to the court for spreading false information to cause financial loss to public company. It is not a free speech to publish manipulated data to support your arguments. Facts supported by accepted mathematical and statistics methods is not a matter of your opinion. You admitted that you hoped and wished that Vyleesi will not get approved….who in his world want a drug under development to fail?

  • This is the same hack that tried to kill PTN’s momentum after a successful phase 3 trial.

    Trusting him will cost you money.

  • Are you a medical professional or a woman, what makes you an expert besides the fact that you probably bet against it!

  • Sounds like sour grapes from a short seller. He was honest enough to say he thought it would be rejected.

    Addyi didnt make any money because it doesnt do anything and it has to be taken every day.

    I don’t have the time to refute all your false facts, but 80% of the women who were part of the trials wanted to continue.

    Sorry your short position is underwater dude

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy